Data / Form D filings / TenNor Therapeutics (Suzhou) Ltd
TenNor Therapeutics (Suzhou) Ltd: Form D filing
TenNor Therapeutics (Suzhou) Ltd, a biotechnology company in Suzhou, China, filed a Form D with the SEC in 2026. The latest, on May 26, 2026, reports $14.7 million sold of a $14.7 million offering to 1 investor.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- UNIT 701, BLOCK B7, BIOBAY 218 XINGHU STREET, Suzhou, China, 21512
- Phone
- 008651286861990
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- China
- Revenue range
- No Revenues
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 2136090
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| May 26, 2026 | New notice | $14,699,667 | $14,699,667 | 1 | May 12, 2026 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Zhenkun Ma | Executive Officer, Director | |
| Gaoguang Song | Director | |
| Michael James Bakes | Director | |
| Wai Kong Lee | Director | |
| Lin Ni | Director | |
| Leping Li | Director | |
| Jie Bi | Executive Officer | |
| Guozhu Geng | Executive Officer | |
| Jing Chen | Executive Officer | |
| Yinjiao Yu | Executive Officer | |
| Rongping Chen | Executive Officer |
Every Form D from the week of May 25, 2026 · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what TenNor Therapeutics (Suzhou) Ltd reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.